DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome

DNA methyltransferase inhibitor, 5-azacitidine (AC) is effective in myelodysplastic syndromes (MDS) and can induce re-expression in cancer. We analyzed the methylation of 25 tumor suppressor genes in AC-treated MDS. Hypermethylation of CDKN2B, FHIT, ESR1, and IGSF4 gene was detected in 9/44 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Huong Thi Thanh, Kim, Hee Nam, Lee, Il-Kwon, Kim, Yeo-Kyeoung, Ahn, Jae-Sook, Yang, Deok-Hwan, Lee, Je-Jung, Kim, Hyeoung-Joon
Formato: Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031004/
https://www.ncbi.nlm.nih.gov/pubmed/21286011
http://dx.doi.org/10.3346/jkms.2011.26.2.207
Descripción
Sumario:DNA methyltransferase inhibitor, 5-azacitidine (AC) is effective in myelodysplastic syndromes (MDS) and can induce re-expression in cancer. We analyzed the methylation of 25 tumor suppressor genes in AC-treated MDS. Hypermethylation of CDKN2B, FHIT, ESR1, and IGSF4 gene was detected in 9/44 patients. In concordance with the clinical response, a lack of or decreased methylation in 4 patients with hematologic improvements and persistent methylation in 4 others with no response was observed. The mRNA expression of CDKN2B, IGSF4, and ESR1 was significantly reduced in MDS. Our results suggest that methylation changes contribute to disease pathogenesis and may serve as marker to monitor the efficacy of treatments.

Ejemplares similares